Physician profile
Dmitriy Dvoskin
NPI 1518224583
$6,281.66
in general payments reported to CMS, 2019-2025
37 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 80% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $229 · 2021: $512 · 2022: $1,085 · 2023: $748 · 2024: $814 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,816.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,942.65 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.63 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $412.29 | 2019-2024 | Superion Indirect Decompression System |
| Nevro Corp. | $345.24 | 2019-2022 | |
| Abbott Laboratories | $338.97 | 2021-2024 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $315.82 | 2022 | |
| Abbvie INC. | $284.04 | 2022-2025 | Ubrelvy, Qulipta |
| Relievant Medsystems, INC. | $252.22 | 2019-2020 | |
| Mml US, INC. | $237.47 | 2023 | Reactiv8 |
| Globus Medical, INC. | $232.10 | 2025 | Senza |
| Indivior INC. | $222.20 | 2024-2025 | Sublocade |
| Stimwave Technologies Incorporated | $211.73 | 2019-2022 | |
| Pfizer INC. | $86.15 | 2019-2024 | |
| Saluda Medical Americas, INC. | $80.90 | 2024-2025 | Evoke |
| Vertex Pharmaceuticals Incorporated | $73.42 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $61.70 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $61.31 | 2022-2024 | Orthovisc |
| Nalu Medical, INC. | $61.05 | 2023 | Nalu Neurostimulation System |
| Horizon Therapeutics Plc | $56.99 | 2021-2022 | |
| Eisai INC. | $53.71 | 2025 | |
| Lilly USA, LLC | $52.63 | 2021-2022 | |
| Painteq LLC | $47.54 | 2021-2024 | Painteq |
| Spinal Simplicity, LLC | $41.30 | 2024-2025 | Ha Minuteman G3-R |
| Valinor Pharma, LLC | $39.47 | 2025 | Movantik |
| Hikma Pharmaceuticals USA | $38.38 | 2022 | |
| Grt US Holding, INC. | $24.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.24 | 2021 | |
| Convatec INC. | $22.49 | 2024 | |
| Redhill Biopharma INC. | $22.37 | 2022 | |
| Almatica Pharma LLC | $21.91 | 2023 | Gralise |
| Virtus Pharmaceuticals LLC | $18.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.78 | 2022 | |
| Biodelivery Sciences International, INC. | $17.65 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.70 | 2025 | |
| Braeburn INC. | $15.91 | 2025 | Brixadi |
| Tonix Medicines, INC. | $15.18 | 2025 | Zembrace Symtouch |
| Neuronetics, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Dvoskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.